BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21724708)

  • 1. Plectranthus amboinicus attenuates inflammatory bone erosion in mice with collagen-induced arthritis by downregulation of RANKL-induced NFATc1 expression.
    Hsu YC; Cheng CP; Chang DM
    J Rheumatol; 2011 Sep; 38(9):1844-57. PubMed ID: 21724708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
    Kwak HB; Lee BK; Oh J; Yeon JT; Choi SW; Cho HJ; Lee MS; Kim JJ; Bae JM; Kim SH; Kim HS
    Bone; 2010 Mar; 46(3):724-31. PubMed ID: 19900598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the mechanism of action of herbal therapies in rheumatoid arthritis: is this the road to clinical development and acceptance?
    Mookherjee N; El-Gabalawy H
    J Rheumatol; 2011 Sep; 38(9):1817-9. PubMed ID: 21885502
    [No Abstract]   [Full Text] [Related]  

  • 6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
    Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
    Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion criteria based on DAS28 score: strength of improvement is less dependent on baseline disease activity than expected.
    van der Horst-Bruinsma I
    J Rheumatol; 2011 Sep; 38(9):1820. PubMed ID: 21885503
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.
    Ishizuka Y; Moriwaki S; Kawahara-Hanaoka M; Uemura Y; Serizawa I; Miyauchi M; Shibata S; Kanaya T; Takata T; Taniguchi N; Niida S
    J Bone Miner Res; 2007 Dec; 22(12):1933-42. PubMed ID: 17680722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.
    Cheng CP; Huang HS; Hsu YC; Sheu MJ; Chang DM
    J Clin Immunol; 2012 Aug; 32(4):762-77. PubMed ID: 22396044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taurine chloramine inhibits osteoclastogenesis and splenic lymphocyte proliferation in mice with collagen-induced arthritis.
    Wang Y; Cha YN; Kim KS; Kim C
    Eur J Pharmacol; 2011 Oct; 668(1-2):325-30. PubMed ID: 21816143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 26 suppresses receptor activator of nuclear factor κB ligand induced osteoclastogenesis via down-regulation of nuclear factor of activated T-cells, cytoplasmic 1 and nuclear factor κB activity.
    Peng YJ; Wang CY; Lin YH; Lin GJ; Huang SH; Shyu JF; Sytwu HK; Cheng CP
    Rheumatology (Oxford); 2016 Nov; 55(11):2074-2083. PubMed ID: 27550297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.